Drug intelligence / Profile preview

Ruquan Keli

Development stage: Unknown
Lead developer: Jiangxi Jingtong Meilian Pharmaceutical
Administration: Oral

Overview

Ruquan Keli is a Traditional Chinese Medicine (TCM) formulated as oral granules, manufactured by Jiangxi Jingtong Meilian Pharmaceutical. It is primarily indicated for the treatment of postpartum hypogalactia (insufficient breast milk production) resulting from deficiency of qi and blood. The herbal formulation is designed to nourish blood, replenish qi, and unblock the breast meridians to stimulate and increase lactation in nursing mothers. As a multi-component herbal product, it functions through the synergistic effects of various botanical constituents to regulate physiological functions related to milk secretion.

Brand names: Ruquan
Other names: Ruquan granules乳泉颗粒

Beyond the preview

Go deeper on Ruquan Keli.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ruquan Keli.

Explore the full profile